Imaging tools to see if immunotherapy is working

some continue treatment even though it may not be effective and a few may develop adverse reaction to the immunotherapy. CellSight's PET tracers provide clinicians with imaging tools to assess immunotherapy response early in the treatment cycle to make informed decisions.
Cancer immunotherapies that harness the body's immune system to help fight cancer do not work for everyone; in fact, success rates can be as low as 20%! Many patients seem to get worse before symptoms ease and clinical benefit can be observed. Some patients may discontinue treatment too early,

Latest News

November 8, 2017
CellSight announces strategic collaboration with Boehringer Ingelheim

September 19, 2017
CellSight and Telix Pharmaceuticals conclude collaboration and license agreement for VisAcT